Acumen is the latest player to take aim at amyloid, but competition is fierce.
Grifols has announced intriguing results in a subgroup of patients in a large Alzheimer's disease study, Ambar, but the finding could also benefit other suppliers of…
Celgene is getting unwanted attention for the high price of Revlimid, but its pivotal position in multiple myeloma could help the company resist a shame campaign.
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.
Either buyers are being pickier or the pool of targets is dwindling.